NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
NGL Fine-Chem Q2 FY27: Revenue Up 32% YoY to ₹158.7 Cr; Phase II Commissioned
NGL Fine-Chem released its Q2 FY27 investor presentation reporting revenue from operations of ₹158.71 Cr, up 31.97% YoY and 14.05% QoQ. Operating EBITDA surged 63.52% YoY to ₹28.06 Cr with margins expanding 341 bps YoY to 17.68%, while PAT rose 68.74% YoY to ₹16.25 Cr. The company commissioned its Phase II expansion (total Tarapur capex incurred of ₹220.72 Cr, representing ~41% of TTM revenue), which is expected to ramp up to 30-40% utilization over the next 2-3 quarters. Management noted that near-term operating costs and depreciation will temporarily weigh on margins before operating leverage sets in.
உச்சம் நம்பிக்கை
என்ன மாறியதுNGL Fine-Chem commissioned its Phase II capacity and reported strong Q2 FY27 revenue growth along with updates on US and European regulatory filings.
ஏன் இது முக்கியம்The ₹220.72 Cr cumulative capex substantially expands capacity for animal APIs (95% of revenues), supporting sustained volume growth as the company prepares to enter higher-margin regulated markets.
Revenue from operations (Q2 FY27): ₹158.71 கோடிEBITDA margin (Q2 FY27): 17.68%PAT (Q2 FY27): ₹16.25 கோடிCapex incurred at Tarapur: ₹220.72 கோடிTarapur Capex vs TTM revenue: ~41.2%
📅 குறுகிய காலம்Margin pressures may emerge over the next few quarters as newly added employee, interest, and depreciation costs from Phase II flow into the P&L ahead of full capacity utilization.
📈 நீண்ட காலம்Transitioning the new capacity into regulated markets (US and Europe) represents a structural growth driver that could improve realizations and margins once inspections and registrations conclude.
⚠ அபாய எச்சரிக்கைகள்
Fixed cost absorption risk if Phase II utilization builds up slower than the targeted 30-40%
High product concentration with Animal APIs contributing 95% of total revenues
Regulatory approval delays in transferring European registrations or clearing USFDA audits
👀 கவனிக்க வேண்டியவை
Track the utilization ramp-up of Phase II toward the guided 30-40% level and monitor the progress of European registration transfers by end-2027 along with potential USFDA inspection timelines.
NGL Fine-Chem Fully Commissions ₹222 Cr Tarapur Greenfield Facility with Phase II Launch
NGL Fine-Chem has commenced commercial production of Phase II at its Tarapur Greenfield facility effective September 24, 2026, marking full operationalization of the project. Total capex incurred is approximately ₹222 crore, financed via ₹138 crore in internal accruals and ₹84 crore in bank term loans. This total investment represents ~41.4% of TTM revenue (₹536 crore) and ~69.4% of net worth (₹320 crore). The facility adds flexible manufacturing infrastructure targeted at expanding NGL's API portfolio, including entry into higher-margin regulated markets.
உச்சம் நம்பிக்கை
என்ன மாறியதுPhase II of the Greenfield facility at Tarapur is officially operationalized, completing the entire greenfield expansion.
ஏன் இது முக்கியம்Represents a massive manufacturing expansion (~41.4% of TTM revenue in capex) enabling validation and supply to regulated markets like the US and Europe.
Total investment made: approx. ₹222 croreInvestment vs TTM revenue: ~41.4%Term loan financing: ₹84 கோடிInternal accruals financing: ₹138 கோடிPhase II commencement date: செப்டம்பர் 24, 2026
📅 குறுகிய காலம்Positive sentiment from successful project completion, though operational costs and depreciation could weigh slightly on margins before utilization scales up.
📈 நீண்ட காலம்Transformational capacity that supports long-term revenue growth and enables entry into higher-margin regulated API markets.
⚠ அபாய எச்சரிக்கைகள்
Underutilization risk during initial ramp-up
Regulatory approval lead times for targeted export markets
Higher depreciation and interest costs from ₹84 crore debt addition
👀 கவனிக்க வேண்டியவை
Track capacity ramp-up and fixed overhead absorption in upcoming quarterly results, along with regulatory approval timelines for Western markets.
Q1FY27 PAT Surges 99% YoY to ₹18.4 Cr; ₹210 Cr Tarapur Plant on Track for H2FY27
NGL Fine-Chem released its Q1FY27 investor presentation reporting revenue from operations of ₹139.16 crore, up 33.57% YoY but down 6.75% QoQ. Profit after tax jumped 99.09% YoY and 36.42% QoQ to ₹18.40 crore, supported by inventory gains and a ₹2.50 crore mark-to-market forex gain (versus a ₹4.50 crore loss in Q4FY26). Management guided that margins (EBITDA margin at 16.73%) may moderate as price realizations normalize. The ₹210 crore Greenfield capex at Tarapur is nearing completion with ₹209.71 crore invested through Q1FY27, scheduled for commercial production in H2FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுPresentation outlines Q1FY27 financial performance and confirms Phase II Tarapur Greenfield capex is nearly fully invested (₹209.71 crore of ₹210 crore).
ஏன் இது முக்கியம்The imminent commissioning of the Tarapur facility in H2FY27 represents a substantial capacity increase intended to drive entry into higher-margin regulated markets (US/Europe).
📅 குறுகிய காலம்Earnings trajectory looks solid following strong Q1 margins, though management noted margins will likely moderate slightly in subsequent quarters as pricing normalizes.
📈 நீண்ட காலம்Commissioning of the Tarapur Greenfield unit provides the primary structural lever for volume expansion and higher-margin regulated market product launches over FY27-FY28.
⚠ அபாய எச்சரிக்கைகள்
Margin moderation expected by management as inventory gains normalize
High product concentration in animal health APIs (95% of Q1FY27 revenues)
Earnings sensitivity to forex fluctuations and raw material price volatility
👀 கவனிக்க வேண்டியவை
Track the commissioning and commercialization timeline of the Tarapur Phase II plant in H2FY27, alongside margin sustainability once temporary inventory and forex gains normalize.
99% YoY PAT Growth for NGL Fine-Chem in Q1 FY27; EPS Rises to Rs 29.78
NGL Fine-Chem reported a strong start to FY27 with consolidated net profit rising 99.1% YoY to Rs 18.40 Cr, up from Rs 9.24 Cr in Q1 FY26. Sequentially, PAT grew 36.4% from Rs 13.49 Cr in Q4 FY26, indicating accelerating momentum. The quarterly PAT of Rs 18.40 Cr represents approximately 38% of the entire TTM PAT (Rs 48 Cr), suggesting a significant earnings beat. Profit Before Tax (PBT) also saw a robust increase of 106.7% YoY to Rs 24.48 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுNGL Fine-Chem has delivered a significant step-up in quarterly profitability, with Q1 FY27 PAT nearly doubling YoY and growing 36% sequentially.
ஏன் இது முக்கியம்The strong earnings performance provides a high base for FY27 and suggests improved operational efficiency or better product mix, crucial as the company targets higher-margin regulated markets.
Consolidated PAT (Q1 FY27): Rs 18.40 கோடிYoY PAT Growth: 99.1%Q1 PAT vs TTM PAT: 38.3%Consolidated EPS: Rs 29.78Finance Costs: Rs 0.97 கோடி
📅 குறுகிய காலம்The stock is likely to react positively in the short term due to the substantial YoY and QoQ profit growth which exceeds the TTM run rate.
📈 நீண்ட காலம்Long-term value depends on the successful commissioning of the Tarapur plant in H2 FY27 and the ability to maintain margins while entering competitive regulated markets.
⚠ அபாய எச்சரிக்கைகள்
High product concentration in animal health (90%)
Raw material price volatility
Intense competition in semi-regulated markets
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution timeline of the Rs 160 Cr Tarapur Greenfield plant scheduled for H2 FY27 and the progress of product validations for regulated US/Europe markets.
NGL Fine-Chem FY26 PAT Surges 128% to ₹48 Cr; ₹160 Cr Tarapur Phase II Set for H2 FY27
NGL Fine-Chem has released its FY26 Annual Report and scheduled its 45th AGM for August 25, 2026. The company reported a strong recovery in FY26 with revenue growing 36% to ₹501 crore and PAT surging 128% to ₹48.13 crore, driven by volume growth and better capacity utilization. A key growth driver is the ₹160 crore Tarapur greenfield expansion, with Phase II expected to commence commercial production in H2 FY27. The company is strategically pivoting toward regulated markets (US/Europe) to diversify its current 94% revenue dependence on Animal APIs.
உச்சம் நம்பிக்கை
என்ன மாறியதுRelease of the FY26 Annual Report and formal notice for the 45th Annual General Meeting scheduled for August 25, 2026.
ஏன் இது முக்கியம்The report confirms a significant margin recovery (EBITDA more than doubled) and provides a concrete timeline for the ₹160 crore capex, which is critical for the company's transition to regulated markets.
FY26 Revenue: ₹500.95 கோடிFY26 PAT Growth: 128%Tarapur Capex Value: ₹160 கோடிCapex vs Net Worth: ~50%Animal API Revenue Share: 94%Dividend per share: ₹1.75
📅 குறுகிய காலம்The stock may react positively to the confirmed strong financial recovery and clear guidance on the Tarapur expansion timeline.
📈 நீண்ட காலம்The structural shift toward regulated markets and the doubling of EBITDA suggests a potential re-rating if the new capacity is successfully utilized in US/Europe markets.
👀 கவனிக்க வேண்டியவை
Monitor the execution and commissioning timeline of the Tarapur Phase II plant in H2 FY27 and the success of regulatory filings (CEP/ASMF) for entry into high-margin regulated markets.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
NGL Fine-Chem FY26 PAT Jumps 128% to ₹48.13 Cr; Revenue Crosses ₹500 Cr Mark
NGL Fine-Chem reported a strong recovery in FY26, with annual revenue growing 36% to ₹500.95 crores and PAT surging 128% to ₹48.13 crores. Q4 FY26 performance was particularly robust, with revenue up 57% YoY to ₹149.23 crores and EBITDA margins expanding by 769 bps to 14.35%. While Phase II expansion at Tarapur is slightly delayed to early Q2 FY27 due to labor and gas shortages, Phase I is already contributing to volume growth. The company has secured partial price pass-throughs to offset rising freight and raw material costs entering FY27.
முக்கிய அம்சங்கள்
FY26 Revenue grew 36% YoY to ₹500.95 crores, while EBITDA more than doubled to ₹72.69 crores.Q4 FY26 PAT stood at ₹13.49 crores compared to just ₹0.54 crores in the same quarter last year.Phase II Greenfield expansion capex increased to ₹210 crores, with ₹182.75 crores already invested as of March 2026.Animal API segment continues to dominate the business mix, contributing 95% of total revenues.Company targets a total of 6 CEPs and 9 DMFs by the end of the calendar year to strengthen its regulated market presence.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commissioning of Phase II in Q2 FY27 and the subsequent commercial production ramp-up in H2 FY27. The successful price pass-through and strong volume momentum indicate a sustainable recovery in operating margins.
NGL Fine-Chem Q4 FY26 PAT Surges 2,380% YoY; FY26 Revenue Crosses ₹500 Crore Mark
NGL Fine-Chem reported a robust performance in Q4 FY26 with revenue growing 57% YoY to ₹149.23 crore, driven primarily by volume expansion in the Animal API segment. The company's annual PAT for FY26 more than doubled to ₹48.13 crore, while EBITDA margins improved significantly to 14.51% from 9.20% in the previous year. Despite challenges from rising freight costs and a slight delay in Phase II capex commissioning (now expected in Q2 FY27), the management remains optimistic about sustainable growth. The company has successfully initiated price pass-throughs to customers to mitigate raw material cost escalations.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue grew 57.13% YoY to ₹149.23 crore, marking the third consecutive quarter of volume growth.Full-year FY26 PAT increased by 127.83% to ₹48.13 crore compared to ₹21.12 crore in FY25.EBITDA margins for FY26 expanded by 531 bps to 14.51%, despite geopolitical headwinds and higher freight costs.Animal API segment continues to be the primary revenue driver, accounting for 95% of the Q4 FY26 revenue mix.Greenfield expansion at Tarapur is well underway with ₹182.75 crore invested out of a planned ₹210 crore capex.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commissioning of Phase II in Q2 FY27 and the company's ability to maintain margins amidst volatile raw material prices. The strong volume recovery and capacity expansion suggest a positive long-term outlook for this veterinary API leader.
NGL Fine-Chem Re-appoints Key Directors and Recommends ₹1.75 Final Dividend
NGL Fine-Chem has announced the re-appointment of Mr. Rajesh Lawande as Whole-Time Director and Mrs. Sarala Menon as Independent Director, both for five-year terms, ensuring leadership continuity. The Board also recommended a final dividend of ₹1.75 per equity share (35% of face value) for the financial year ended March 31, 2026. The record date for the dividend and the 45th Annual General Meeting is set for August 18, 2026. Additionally, the company has appointed new internal and cost auditors for the 2026-27 fiscal year.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹1.75 per equity share of ₹5 each for FY 2025-26Re-appointed Mr. Rajesh Lawande as Whole-Time Director for 5 years effective June 1, 2026Re-appointed Mrs. Sarala Menon as Independent Director for 5 years effective December 14, 2026Set August 18, 2026, as the record date for dividend eligibility and AGM attendanceAppointed KD Practice Consulting Pvt. Ltd. as Internal Auditors for FY 2026-27
👀 கவனிக்க வேண்டியவை
Investors should maintain their positions as the leadership continuity and dividend payout signal stability. Ensure holdings are in the demat account by the August 18 record date to qualify for the ₹1.75 dividend.
NGL Fine-Chem Announces ₹1.75 Final Dividend; Sets Record Date for August 18, 2026
NGL Fine-Chem Limited has recommended a final dividend of ₹1.75 per equity share of ₹5 face value for the financial year ended March 31, 2026. The company has fixed August 18, 2026, as the record date to determine shareholder eligibility for this payout. Along with the dividend, the Board approved the audited financial results for FY26 and scheduled the 45th Annual General Meeting for August 25, 2026. The Board also approved the re-appointment of Rajesh Lawande as Whole-Time Director for a five-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹1.75 per fully paid-up equity share of ₹5 each.Record date for dividend payment and 45th AGM set for Tuesday, August 18, 2026.45th Annual General Meeting (AGM) scheduled for August 25, 2026, via video conferencing.Re-appointment of Mr. Rajesh Lawande as Whole-Time Director for 5 years effective June 1, 2026.Approved audited standalone and consolidated financial results for the year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors looking to benefit from the ₹1.75 dividend should ensure they hold the stock before the ex-dividend date, typically one business day prior to the August 18 record date. Review the full audited financial statements to assess the company's year-on-year growth and profitability.
NGL Fine-Chem Limited has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The Board recommended a final dividend of ₹1.75 per equity share (35% of the ₹5 face value), with a record date set for August 18, 2026. Key management stability was ensured through the five-year re-appointment of Whole-Time Director Rajesh Lawande. Additionally, the company appointed new internal and cost auditors for the 2026-27 financial year.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹1.75 per fully paid-up equity share of ₹5 each for FY26.Set August 18, 2026, as the record date for dividend payment and the 45th Annual General Meeting.Re-appointed Mr. Rajesh Lawande as Whole-Time Director for a consecutive five-year term effective June 1, 2026.Appointed M/s. KD Practice Consulting Pvt. Ltd. and M/s. Sanghavi Randeria & Associates as Internal and Cost Auditors respectively for FY27.Statutory auditors issued an unmodified opinion on consolidated results, including subsidiary Macrotech Polychem Pvt. Ltd.
👀 கவனிக்க வேண்டியவை
Investors should monitor the detailed profit and loss statements for margin trends while noting the management continuity as a positive sign for long-term strategy execution.
NGL Fine-Chem Credit Rating Outlook Upgraded to 'Stable' from 'Negative'
CRISIL Ratings has revised the outlook on NGL Fine-Chem Limited's long-term bank loan facilities to 'Stable' from 'Negative'. While the outlook has improved, the long-term rating itself has been reaffirmed at 'CRISIL BBB+'. Additionally, the company's short-term rating was reaffirmed at 'CRISIL A2'. This revision indicates a stabilization in the company's credit profile and a reduced risk of a rating downgrade in the near term.
முக்கிய அம்சங்கள்
Outlook on long-term bank facilities revised to 'Stable' from 'Negative'Long-term credit rating reaffirmed at 'CRISIL BBB+'Short-term credit rating reaffirmed at 'CRISIL A2'Rating action communicated by CRISIL Ratings on March 12, 2026
👀 கவனிக்க வேண்டியவை
Investors should view the outlook upgrade as a sign of improving financial stability; however, continue to monitor quarterly earnings for sustained operational growth.
NGL Fine-Chem Q3FY26 PAT Jumps 1129% YoY to ₹15.69 Cr; EBITDA Margin Hits 17.5%
NGL Fine-Chem reported a robust Q3FY26 with revenue growing 43.11% YoY to ₹127.51 crore, driven by higher volumes and stable realizations. Profitability saw a massive jump, with PAT rising over 11-fold to ₹15.69 crore and EBITDA margins expanding to 17.50% from 5.72% a year ago. The company's major greenfield expansion at Tarapur is on track with a revised investment of ₹210 crore, targeting commissioning in Q1FY27. Management expects commercial production from this facility to start in H2FY27, aiming for an asset turnover of over two times.
முக்கிய அம்சங்கள்
Revenue from operations grew 43.11% YoY to ₹127.51 crore in Q3FY26.EBITDA margin improved significantly to 17.50% compared to 5.72% in the previous year's quarter.Animal API remains the core segment, contributing 92% of the total revenue mix.Greenfield expansion project cost revised to ₹210 crore with ₹156 crore already invested; commissioning expected in Q1FY27.Debt for the expansion project is capped at ₹85 crore, with the remainder funded via internal accruals.
👀 கவனிக்க வேண்டியவை
Investors should note the significant margin recovery and the upcoming capacity expansion which could drive the next leg of growth. Monitor the commissioning of the Tarapur facility in Q1FY27 and the subsequent ramp-up in H2FY27.
NGL Fine-Chem Q3 PAT Surges to ₹15.69 Cr; Revenue Up 43% YoY
NGL Fine-Chem reported a stellar performance for Q3 FY26, with consolidated net profit jumping to ₹15.69 crore from just ₹1.28 crore in the same quarter last year. Revenue from operations grew by 43.1% YoY to ₹127.51 crore, reflecting strong operational recovery. For the nine-month period ending December 2025, the company has already surpassed its full-year FY25 profit, reaching ₹34.56 crore. Additionally, the company appointed Shivam Gharat as the new Company Secretary and Compliance Officer.
முக்கிய அம்சங்கள்
Consolidated Net Profit rose exponentially to ₹15.69 crore in Q3 FY26 from ₹1.28 crore in Q3 FY25.Revenue from operations increased 43.1% YoY to ₹127.51 crore compared to ₹89.10 crore in the previous year.Basic EPS saw a massive jump to ₹25.40 in Q3 FY26 from ₹2.07 in the year-ago period.Nine-month consolidated PAT stands at ₹34.56 crore, significantly higher than the ₹20.31 crore reported in the same period last year.Shivam Gharat appointed as Company Secretary and Compliance Officer effective February 3, 2026.
👀 கவனிக்க வேண்டியவை
The company is showing strong growth momentum with nine-month profits already exceeding the previous full year's performance. Investors should maintain a positive outlook while monitoring the impact of new labour code regulations on future employee benefit costs.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
